OncoSec Medical Inc. To Present At ICV Manhattan
SAN DIEGO, Dec. 2, 2015 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that CEO and President Punit Dhillon will present a corporate overview at Investment Community Visibility (ICV) Manhattan on Tuesday, December 8, 2015 in New York City. The presentation is scheduled to begin at 1:45 PM ET at the Mandarin Oriental Hotel.
ICV Manhattan provides a platform for approximately 50 chief executives at innovative growth companies to meet and share ideas with members of ICV's investment community. This two-day event will allow family office and fund investors to capitalize on new ideas and businesses that are shaping the future of traditional industries. In addition to company presentations, experts will discuss the current landscape of their respective fields through participation in thought leader panels and roundtable discussions. For more information, please visit: http://www.icvevents.com/.
About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse, for the treatment of cancer. ImmunoPulse is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse IL-12, is currently in Phase II development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. In addition to ImmunoPulse IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse platform. For more information, please visit www.oncosec.com.
Contact
Investor Relations:
Jordyn Kopin
OncoSec Medical Incorporated
855-662-6732
investors@oncosec.com
Media Relations:
Mary Marolla
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
Logo - http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oncosec-to-present-at-icv-manhattan-300186679.html
SOURCE OncoSec Medical Incorporated
